fda green list import alert 66-80 glp-1 semaglutide tirzepatide SFDA updates guidelines for pharmaceutical variation requirements FDA Launches “Green List” to

E.ZhouJ

What This Means for Patients If youre a patient reading this wondering what it means for you, heres what Id want you to know

Notably, the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial, the first dedicated kidney outcome trial evaluating canagliflozin in people with type 2 diabetes mellitus and CKD, demonstrated a substantial reduction in the risk of kidney events [46]

Lilly is committed to collaborating with the government and industry to promote awareness and improve the prevention and management of these diseases, said Winselow Tucker, President and General Manager, Eli Lilly India